Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 14.08.25 18:22:06 |
MediWound Revenue Jumps 43% in Q2 |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Here's a German summary of the provided text, aiming for approximately 400 words:
**MediWound veröffentlicht starke Ergebnisse im zweiten Quartal 2025**
MediWound (NASDAQ:MDWD) gab am 14. August 2025 seine Ergebnisse für das zweite fiskalische Quartal 2025 bekannt, wobei der Umsatz um 43% gegenüber dem Vorquartal auf 5,7 Millionen US-Dollar anstieg. Dieser deutliche Anstieg wurde durch höhere Produktverkäufe und eine günstige Produktmix-Entwicklung vorangetrieben. Das Unternehmen hat seine Phase-III-EscharEx VALUE-Studie vorangetrieben, seine U.S.-Präsenz von NexoBrid erweitert und die Produktion sukzessive hochskaliert, um die globale Nachfrage zu decken. Strategische Partnerschaften und operative Meilensteine positionieren MediWound für weiteres Wachstum und regulatorische Fortschritte.
**Erweiterte Partnerschaften für EscharEx Validierung**
Im Laufe des Quartals etablierte MediWound neue Kooperationen mit führenden Wundbehandlung Unternehmen wie ConvaTec (LSE:CTEC) und SCT, ergänzend zu bestehenden Partnerschaften mit Solventum (NYSE:SOLV) und Mölnlycke. Diese Kooperationen decken nun alle wichtigen Kategorien von Standard-of-Care-Produkten ab, die in klinischen Protokollen integriert sind, und unterstützen sowohl die laufende Phase-III-Studie für venöse Beinknöterkrankungen (VLU) als auch die geplante Studie für diabetische Fußulkus (DFU).
“Im zweiten Quartal haben wir kontinuierlich unsere Ziele in den Bereichen Klinik, Vertrieb und Betrieb erreicht. Die EscharEx VALUE Phase III-Studie läuft aktiv und mit der Etablierung neuer Partnerschaften mit ConvaTec und SCT sind alle wichtigen globalen Wundbehandlungsexperten in unseren klinischen Programmen involviert”, erklärte Ofer Gonen, CEO.
Dieses breite Netzwerk von Industriepartnern reduziert das Risiko einer geringen Akzeptanz und positioniert EscharEx für eine weitverbreitete Anwendung in der Praxis, da klinische Protokolle die Vielfalt der Standardwundbehandlungspraktiken in wichtigen Märkten widerspiegeln.
**Verbesserte Margen und Wachstum von NexoBrid**
Die Ergebnisse von MediWound im Q2 zeigen eine Verbesserung der Rohmarge, die auf 23,5% stieg, verglichen mit 8,8% im zweiten Quartal des Geschäftsjahres 2024. Der Umsatz stieg um 52% im Vergleich zum Vorjahr für den NexoBrid-Partner Vericel (NASDAQ:VCEL), was einen nachhaltigen Verkaufsdruck unterstreicht, obwohl die Nachschubversorgung voll ausgelastet blieb.
“Der Umsatz für das Quartal betrug 1,3 Millionen US-Dollar oder 23,5% des Umsatzes, verglichen mit 400.000 US-Dollar oder 8,8% im Vorjahreszeitraum. Die Margenverbesserung spiegelt einen günstigeren Produktmix wider. Die Forschungs- und Entwicklungskosten beliefen sich auf 3,5 Millionen US-Dollar, verglichen mit 1,9 Millionen US-Dollar im Jahr 2024, was die Investitionen in die EscharEx VALUE Phase III-Studie widerspiegelt”, erklärte Hani Luxenburg, CFO.
**NexoBrid Produktionsanlage und erwartete Genehmigungen**
Die neue Produktionsanlage befindet sich weiterhin auf Kurs für den Abschluss und die Einreichung bei den Aufsichtsbehörden bis Ende 2025, wobei die EMA-Stabilitätsprüfung drei Monate und die FDA-Prüfung sechs Monate dauern werden. Die erwarteten Genehmigungen in Europa und den USA werden voraussichtlich im Jahr 2026 erfolgen. MediWounds Prognose für 24 Millionen US-Dollar Umsatz im Jahr 2025 basiert auf diesen Schätzungen.
“Wir haben von der Fertigstellung der Anlage und der Einreichung bei den Zulassungsbehörden gesprochen. Die Stabilitätsprüfungen in Europa sind drei Monate lang und in den Vereinigten Staaten sechs Monate. Wir schätzen, dass wir 2026 die Genehmigung von der EMA und 2026 die Genehmigung von der FDA erhalten. Die Umsatzprognose, die wir präsentieren, spiegelt diese Schätzungen wider”, fügte Ofer Gonen hinzu.
---
**Note:** This translation strives for accuracy and a natural-sounding German style. I have focused on clarity and readability. |
| 15.07.25 06:48:08 |
Convatec responds to CMS draft proposal on skin substitutes |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
LONDON - Medical products company Convatec Group PLC (LSE:CTEC) announced on Tuesday it will engage in the public comment process regarding a draft payment proposal from the Centers for Medicare & Medicaid Services (CMS) for skin substitutes in the United States.
The company expressed support for CMS’s efforts to reduce costs and promote responsible market practices, but raised concerns that the proposed reimbursement rate could limit patient choice, product quality and availability in the segment.
Convatec’s InnovaMatrix, a porcine placental-derived extra-cellular matrix for wound treatment, represented approximately 3% of the company’s group revenue in the four months to April 2025. The company expects revenue of at least $75 million from the product in fiscal year 2025.
If implemented in its current form, the proposal could create a potential year-on-year headwind to fiscal year 2026 revenue of approximately 1-2% of group revenue, according to the company statement.
The public comment period for the CMS proposal closes on September 12, 2025, and Convatec noted that any changes would not be expected before 2026 at the earliest.
InnovaMatrix is FDA-cleared for 15 separate medical indications. Convatec stated it remains committed to the segment and is on track to publish randomized controlled trials in 2026, while continuing to develop sales across various indications both within and outside the United States.
The company plans to provide an update to investors at its half-year results on July 29, 2025.
Convatec, a constituent of the FTSE 100 Index, reported revenues of over $2 billion in 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. |
| 24.06.25 06:37:59 |
UK's June 2025 Stocks That May Be Trading Below Fair Value |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
In the last week, the United Kingdom market has been flat, yet it has shown a 4.0% increase over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and positive earnings projections, identifying stocks that may be trading below their fair value could present potential investment opportunities for those looking to capitalize on undervalued assets.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name Current Price Fair Value (Est) Discount (Est) Vistry Group (LSE:VTY) £6.274 £10.79 41.9% LSL Property Services (LSE:LSL) £3.15 £5.66 44.3% Jubilee Metals Group (AIM:JLP) £0.035 £0.066 46.7% Huddled Group (AIM:HUD) £0.0335 £0.06 44% Greatland Gold (AIM:GGP) £0.156 £0.30 48.2% Gooch & Housego (AIM:GHH) £5.90 £10.54 44% Franchise Brands (AIM:FRAN) £1.46 £2.56 43% Duke Capital (AIM:DUKE) £0.295 £0.54 44.9% Deliveroo (LSE:ROO) £1.757 £3.07 42.8% AstraZeneca (LSE:AZN) £104.20 £180.84 42.4%
Click here to see the full list of 54 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Aptitude Software Group
Overview: Aptitude Software Group plc, with a market cap of £191.29 million, provides financial management software in the United Kingdom and internationally through its subsidiaries.
Operations: The company generates revenue of £70.04 million from its Aptitude Software segment, focusing on financial management solutions globally.
Estimated Discount To Fair Value: 32.9%
Aptitude Software Group is trading significantly below its estimated fair value, presenting potential as an undervalued stock based on cash flows. Earnings are projected to grow at 24.3% annually, outpacing the UK market's growth rate. Recent developments include a strategic board appointment and securing a $1 million Fynapse contract, enhancing its recurring revenue base. Despite a slight decline in sales last year, net income improved, indicating robust financial health amidst strategic expansions.
Insights from our recent growth report point to a promising forecast for Aptitude Software Group's business outlook. Navigate through the intricacies of Aptitude Software Group with our comprehensive financial health report here.LSE:APTD Discounted Cash Flow as at Jun 2025
ConvaTec Group
Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.92 billion.
Operations: The company's revenue segment is primarily focused on the development, manufacture, and sale of medical products and technologies, generating $2.29 billion.
Story Continues
Estimated Discount To Fair Value: 19.6%
ConvaTec Group trades below its estimated fair value, suggesting potential as an undervalued stock based on cash flows. With earnings forecast to grow at 17.22% annually, it surpasses the UK market's growth rate. Recent global collaborations in healthcare education highlight its commitment to quality care and market expansion. Despite a high debt level, the company's revenue is expected to outpace the broader UK market, reflecting solid growth prospects amidst strategic initiatives.
The analysis detailed in our ConvaTec Group growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of ConvaTec Group.LSE:CTEC Discounted Cash Flow as at Jun 2025
Foresight Group Holdings
Overview: Foresight Group Holdings Limited is an infrastructure and private equity manager operating in the UK, Italy, Luxembourg, Ireland, Spain, and Australia with a market cap of £447.18 million.
Operations: The company's revenue segments include £87.79 million from Infrastructure, £50.78 million from Private Equity, and £8.10 million from Foresight Capital Management.
Estimated Discount To Fair Value: 29.8%
Foresight Group Holdings is trading below its fair value estimate of £5.67, presenting an opportunity as an undervalued stock based on cash flows. The company announced a £50 million share buyback program, financed from existing and future cash resources, enhancing shareholder value. With earnings forecast to grow at 26.6% annually, outpacing the UK market's growth rate, and a high return on equity projected at 52.5%, Foresight demonstrates strong financial prospects despite recent one-off items impacting results.
According our earnings growth report, there's an indication that Foresight Group Holdings might be ready to expand. Delve into the full analysis health report here for a deeper understanding of Foresight Group Holdings.LSE:FSG Discounted Cash Flow as at Jun 2025
Where To Now?
Investigate our full lineup of 54 Undervalued UK Stocks Based On Cash Flows right here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Ready To Venture Into Other Investment Styles?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:APTD LSE:CTEC and LSE:FSG.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 23.05.25 06:37:47 |
UK's May 2025 Stocks That Could Be Trading Below Fair Value |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
As the UK market navigates the challenges posed by fluctuating global trade dynamics, particularly with China's economic struggles impacting the FTSE 100, investors are keenly observing opportunities that may arise from these uncertainties. In such a climate, identifying stocks that could be trading below their fair value becomes crucial for those looking to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name Current Price Fair Value (Est) Discount (Est) Savills (LSE:SVS) £9.42 £16.43 42.7% Aptitude Software Group (LSE:APTD) £2.90 £5.13 43.5% Big Technologies (AIM:BIG) £1.08 £2.09 48.3% Victrex (LSE:VCT) £8.00 £15.44 48.2% Informa (LSE:INF) £8.01 £15.23 47.4% SDI Group (AIM:SDI) £0.74 £1.37 46.1% Vistry Group (LSE:VTY) £5.838 £11.24 48.1% Entain (LSE:ENT) £7.418 £13.79 46.2% Duke Capital (AIM:DUKE) £0.2925 £0.53 44.8% Deliveroo (LSE:ROO) £1.756 £3.05 42.5%
Click here to see the full list of 51 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
Let's explore several standout options from the results in the screener.
Big Technologies
Overview: Big Technologies PLC, operating under the Buddi brand, develops and delivers remote monitoring technologies and services for the offender and personal monitoring industry across the Americas, Europe, and Asia-Pacific, with a market cap of £311.18 million.
Operations: Big Technologies PLC generates revenue through its development and provision of remote monitoring technologies and services for the offender and personal monitoring sectors across various regions, including the Americas, Europe, and Asia-Pacific.
Estimated Discount To Fair Value: 48.3%
Big Technologies is trading significantly below its estimated fair value, presenting a potential opportunity for investors focused on cash flow valuation. Despite a recent decline in net income to £2.42 million from £16.19 million, the company's earnings are expected to grow substantially at 35% annually, outpacing the UK market's growth rate of 14.2%. However, revenue growth forecasts remain modest at 3.8% per year amidst recent management changes and volatile share prices.
Our expertly prepared growth report on Big Technologies implies its future financial outlook may be stronger than recent results. Take a closer look at Big Technologies' balance sheet health here in our report.AIM:BIG Discounted Cash Flow as at May 2025
ConvaTec Group
Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.72 billion.
Operations: The company's revenue from the development, manufacture, and sale of medical products and technologies amounts to $2.29 billion.
Story Continues
Estimated Discount To Fair Value: 21.7%
ConvaTec Group is trading over 20% below its estimated fair value of £3.57, indicating potential undervaluation based on cash flows. The company's earnings are forecast to grow at 16.9% annually, surpassing the UK market's growth rate. Recent financial results show an increase in net income to US$190.5 million from US$130.3 million year-over-year, alongside a strategic collaboration with WOCN® to enhance ostomy care education globally, reinforcing its commitment to healthcare improvement.
Our comprehensive growth report raises the possibility that ConvaTec Group is poised for substantial financial growth. Unlock comprehensive insights into our analysis of ConvaTec Group stock in this financial health report.LSE:CTEC Discounted Cash Flow as at May 2025
SSP Group
Overview: SSP Group plc operates food and beverage outlets across North America, Europe, the United Kingdom, Ireland, the Asia Pacific, Eastern Europe, the Middle East, and internationally with a market cap of approximately £1.40 billion.
Operations: The company's revenue is primarily derived from the food and beverage travel sector, mainly at airports and railway stations, amounting to £3.58 billion.
Estimated Discount To Fair Value: 36.6%
SSP Group is trading at £1.75, significantly below its estimated fair value of £2.75, suggesting it is undervalued based on cash flows. The company's revenue growth forecast of 5.2% annually outpaces the UK market and earnings are expected to grow 57.5% per year, with profitability anticipated in three years. Despite a net loss of £61.5 million for H1 2025, its high future return on equity and good relative valuation offer potential upside.
The growth report we've compiled suggests that SSP Group's future prospects could be on the up. Click here to discover the nuances of SSP Group with our detailed financial health report.LSE:SSPG Discounted Cash Flow as at May 2025
Summing It All Up
Unlock our comprehensive list of 51 Undervalued UK Stocks Based On Cash Flows by clicking here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Contemplating Other Strategies?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:BIG LSE:CTEC and LSE:SSPG.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 31.03.25 08:00:00 |
Convatec Announces Exclusive Collaboration With Largest Wound, Ostomy and Continence Professional Nursing Organisation |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Unique global programme and collaboration with Wound, Ostomy, and Continence Nurses Society™ (WOCN®) set to support healthcare professionals
LONDON, March 31, 2025--(BUSINESS WIRE)--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, is excited to announce its global collaboration with the Wound, Ostomy, and Continence Nurses Society™ (WOCN®), the largest and most recognised professional nursing community dedicated to advancing the practice and delivery of expert healthcare to individuals with wound, ostomy, and continence care needs.
Together, Convatec and WOCN are announcing two best-in-class, free, educational initiatives to enhance general ostomy care knowledge for healthcare professionals as many facilities do not have enough trained staff in this area. The two initiatives include the online Advanced Ostomy Care Program and the Ostomy Care Associates (OCA®) Program, both designed to enhance the standard of care ostomy patients receive by providing education for both specialised and non-specialised healthcare professionals. These programmes will be available* in the United States, United Kingdom, Ireland, Brazil, Poland and China in 2025, with the first programmes launching in the US, UK and Ireland.
Bruno Pinheiro, President & Chief Operating Officer, Ostomy Care at Convatec said: "Forever caring is the promise we make to our customers, including patients, consumers and healthcare professionals. We are delighted to launch this new collaboration with the WOCN Society to offer education that we believe will give more patients access to best-in-class ostomy care and improve quality of life for the growing number of people living with an ostomy worldwide."
Dr. Tod Brindle PhD, Medical Affairs Director, Ostomy Care at Convatec said: "Supporting healthcare professionals in this way helps Convatec achieve our mutual goals of enhancing patient care, providing access to specialised care where ostomy services are limited, and improving the quality of life for those we serve. This exciting opportunity for existing ostomy care healthcare professionals worldwide, led by our specialist teams, will enhance their knowledge and elevate the standard of care for people with an ostomy, while also striving to train over 750 new healthcare professionals to deliver specialised care to ostomates."
Vittoria (Vicky) Pontieri-Lewis, MS, RN, ACNS-BC, CWOCN, President of the WOCN Society, said: "We are grateful to Convatec for making this unique programme possible. This collaboration will expand access to continuing education in ostomy care, ultimately helping individuals with ostomies benefit from current evidence-based practices and receive the optimal care they deserve."
Story Continues
Advanced Ostomy Care Program Convatec has curated a library of complimentary self-paced on-demand online courses developed and administered by WOCN. The courses selected were chosen by experts in ostomy care because they will help equip healthcare providers with the specialised knowledge and skills needed to offer optimal pre-operative, post-operative and ongoing care.
The Ostomy Care Associate (OCA) Program WOCN recognises that many healthcare facilities do not have enough staff trained in ostomy care and developed the OCA Program to enhance the general ostomy care knowledge for the entire nursing team with the goal of improving patient outcomes. Convatec is investing in the expansion by offering it at no cost to select facilities and managing the administration of the curriculum initiative, and through highly qualified ostomy care experts.
The expansion underscores Convatec’s commitment to improving knowledge for healthcare professionals and ensuring that people living with an ostomy receive superior care that improves their quality of life. All participants will receive a certificate of completion awarded by the WOCN Society. Licensed nurses in the US are eligible and will receive Contact Hours upon completing the programme.
Since its inception in 2017, over 1,000 people have completed the OCA Program. Of those, 100% have reported that their professional knowledge and skills were updated, 99.6% have reported that they plan on making changes in their practice based on this educational activity, and 100% would recommend this activity to others.
*Access to these programmes is being granted by an unrestricted educational grant.
Notes to editors
You can find more information on the UK and Ireland webpages here and on the US webpages here.
About Convatec Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
About the Wound, Ostomy, and Continence Nurses Society™ Founded in 1968, the Wound, Ostomy, and Continence Nurses Society™ (WOCN®) is the largest and most recognised professional nursing community dedicated to advancing the practice and delivery of expert healthcare to individuals with wound, ostomy, and continence care needs. Through relevant education, effective advocacy, cutting-edge science, a supportive network, and a patient-centric approach, the Society enables professional growth for 5,000+ members and aids in improving patient outcomes. Visit wocn.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331342836/en/
Contacts
Media: MediaRelations@convatec.com
Investor relations: ir@convatec.com
View Comments |
| 07.03.25 06:07:48 |
UK Stocks That Might Be Trading Below Their Estimated Value In March 2025 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
The United Kingdom's stock market has recently experienced a downturn, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such an environment, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervaluation amid broader market challenges.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name Current Price Fair Value (Est) Discount (Est) Dr. Martens (LSE:DOCS) £0.6105 £1.19 48.6% GlobalData (AIM:DATA) £1.79 £3.37 46.9% Deliveroo (LSE:ROO) £1.257 £2.50 49.6% AstraZeneca (LSE:AZN) £120.28 £219.10 45.1% Duke Capital (AIM:DUKE) £0.3025 £0.55 44.6% Likewise Group (AIM:LIKE) £0.195 £0.37 47.6% Calnex Solutions (AIM:CLX) £0.52 £1.03 49.7% Kromek Group (AIM:KMK) £0.0585 £0.11 48.5% Optima Health (AIM:OPT) £1.82 £3.31 45% Savannah Energy (AIM:SAVE) £0.105 £0.20 48.7%
Click here to see the full list of 57 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
We'll examine a selection from our screener results.
ConvaTec Group
Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.47 billion.
Operations: The company's revenue is primarily generated from the development, manufacture, and sale of medical products and technologies, amounting to $2.29 billion.
Estimated Discount To Fair Value: 36%
ConvaTec Group appears undervalued, trading at £2.67, 36% below its estimated fair value of £4.18. The company's earnings grew by 46.2% last year and are forecast to grow annually at 16.9%, outpacing the UK market's 14.1%. Despite high debt levels, ConvaTec maintains a strong financial position with operating profit growth projected at 12% for 2025 and a net income increase to US$190.5 million from US$130.3 million in the prior year.
Our growth report here indicates ConvaTec Group may be poised for an improving outlook. Take a closer look at ConvaTec Group's balance sheet health here in our report.LSE:CTEC Discounted Cash Flow as at Mar 2025
Genus
Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa and Asia; it has a market cap of £1.25 billion.
Operations: The company's revenue is derived from two main segments: Genus ABS, which contributes £311.10 million, and Genus PIC, which accounts for £358 million.
Estimated Discount To Fair Value: 19%
Genus plc, trading at £19.04, is undervalued relative to its fair value estimate of £23.5. Despite recent earnings showing a decline in net income to £1.5 million from £10.3 million year-on-year, analysts forecast robust profit growth of 46.67% annually over the next three years, outpacing market averages and expected to achieve profitability within this period. However, the stock exhibits high volatility and a low forecasted return on equity of 12.5%.
Story Continues
In light of our recent growth report, it seems possible that Genus' financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Genus.LSE:GNS Discounted Cash Flow as at Mar 2025
PageGroup
Overview: PageGroup plc, along with its subsidiaries, offers recruitment consultancy and related services across the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas with a market cap of £1.05 billion.
Operations: PageGroup generates revenue through its recruitment consultancy and ancillary services across regions including the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas.
Estimated Discount To Fair Value: 14.3%
PageGroup, trading at £3.34, is undervalued compared to its fair value estimate of £3.9. Despite a decline in revenue and net income for 2024, earnings are forecast to grow significantly at 37.6% annually over the next three years, surpassing UK market averages. The company proposed a dividend increase but maintains an unstable dividend track record. Profit margins have decreased from 3.8% to 1.6%, yet return on equity is projected to be high at 35.1%.
Our comprehensive growth report raises the possibility that PageGroup is poised for substantial financial growth. Unlock comprehensive insights into our analysis of PageGroup stock in this financial health report.LSE:PAGE Discounted Cash Flow as at Mar 2025
Summing It All Up
Access the full spectrum of 57 Undervalued UK Stocks Based On Cash Flows by clicking on this link. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Seeking Other Investments?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:CTEC LSE:GNS and LSE:PAGE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 29.01.25 11:02:40 |
Discover Restore And 2 Other UK Stocks That May Be Trading Below Estimated Value |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
The UK stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China, impacting companies closely tied to its economic performance. Amid these conditions, identifying stocks that may be undervalued becomes crucial as investors seek opportunities that could offer potential value despite broader market pressures.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name Current Price Fair Value (Est) Discount (Est) Hercules Site Services (AIM:HERC) £0.495 £0.93 46.5% Gaming Realms (AIM:GMR) £0.367 £0.71 48.7% GlobalData (AIM:DATA) £1.785 £3.57 49.9% On the Beach Group (LSE:OTB) £2.565 £5.03 49% ConvaTec Group (LSE:CTEC) £2.502 £4.92 49.1% Victrex (LSE:VCT) £9.89 £19.52 49.3% Informa (LSE:INF) £8.38 £16.32 48.7% Deliveroo (LSE:ROO) £1.328 £2.64 49.7% BATM Advanced Communications (LSE:BVC) £0.192 £0.38 49.4% St. James's Place (LSE:STJ) £9.47 £18.68 49.3%
Click here to see the full list of 52 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
Let's explore several standout options from the results in the screener.
Restore
Overview: Restore plc, with a market cap of £295.76 million, offers services to offices and workplaces in both the public and private sectors primarily in the United Kingdom.
Operations: The company's revenue is derived from Secure Lifecycle Services, contributing £104.40 million, and Digital & Information Management, generating £172.50 million.
Estimated Discount To Fair Value: 29.4%
Restore is trading at £2.24, significantly below its estimated fair value of £3.17, indicating potential undervaluation based on discounted cash flows. Despite slower revenue growth forecasts of 3.6% annually and flat FY24 revenue due to market uncertainty, earnings are expected to grow significantly at 48.22% per year, outpacing the UK market average. However, interest payments are not well covered by earnings and the dividend yield of 2.39% lacks coverage by current profits.
According our earnings growth report, there's an indication that Restore might be ready to expand. Dive into the specifics of Restore here with our thorough financial health report.AIM:RST Discounted Cash Flow as at Jan 2025
ConvaTec Group
Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.08 billion.
Operations: The company's revenue primarily comes from the development, manufacture, and sale of medical products and technologies, totaling $2.20 billion.
Estimated Discount To Fair Value: 49.1%
ConvaTec Group is trading at £2.50, well below its estimated fair value of £4.92, highlighting potential undervaluation based on discounted cash flows. Earnings have grown significantly by 117.9% in the past year and are forecast to grow 20.35% annually, surpassing UK market averages. However, despite robust profit growth projections and revenue growth forecasts exceeding the UK market rate of 3.6%, ConvaTec carries a high level of debt that may impact financial flexibility.
Story Continues
The analysis detailed in our ConvaTec Group growth report hints at robust future financial performance. Take a closer look at ConvaTec Group's balance sheet health here in our report.LSE:CTEC Discounted Cash Flow as at Jan 2025
Vp
Overview: Vp plc offers equipment rental and associated services both in the United Kingdom and internationally, with a market cap of £236.77 million.
Operations: The company generates revenue through its operations in the United Kingdom, contributing £339.21 million, and international activities, adding £43.35 million.
Estimated Discount To Fair Value: 38.5%
Vp plc is trading at £6.20, significantly below its estimated fair value of £10.07, suggesting potential undervaluation based on discounted cash flows. Despite a high debt level and modest revenue growth forecast of 3.9% annually, Vp's profitability is expected to improve above market averages over the next three years. The recent launch of Vp Rail aligns with its strategic focus on end markets and digital enhancements, potentially supporting future growth despite current earnings not covering dividends adequately.
Our expertly prepared growth report on Vp implies its future financial outlook may be stronger than recent results. Delve into the full analysis health report here for a deeper understanding of Vp.LSE:VP. Discounted Cash Flow as at Jan 2025
Seize The Opportunity
Investigate our full lineup of 52 Undervalued UK Stocks Based On Cash Flows right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Looking For Alternative Opportunities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:RST LSE:CTEC and LSE:VP..
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 06.01.25 14:00:00 |
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
LONDON, January 06, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer.
"Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova."
Kozmina most recently served as Executive Vice President and CHRO of Convatec Group PLC (LSE: CTEC), a London-based global medical technologies company and constituent of the FTSE 100 Index. In this role, she developed and implemented transformative talent strategies to strengthen leadership capabilities across the business and set the foundation for building a winning culture and high-performing teams. She also served in senior human resources leadership roles for Iron Mountain (NYSE: IRM) and Smiths Group (LSE: SMIN).
In April 2024, Kozmina was appointed to the Board of London-based Carclo PLC (LSE: CAR.L), a global high-precision critical components company, as a Non-Executive Director where she chairs the Remuneration Committee and is a member of the Audit and Nomination Committees.
"I am delighted to join the LivaNova team during this time of solid growth and success in its clinical programs," Kozmina said. "I am eager to work with the talented teams across the enterprise to drive HR strategies that align with our values and support employees as they work to improve the lives of patients around the world."
Kozmina, who will be based in Italy, has more than 25 years of global leadership experience for publicly traded companies in highly regulated industries. She spent the first half of her career in the pharmaceutical industry, serving in leadership positions for companies such as Abbott Laboratories (NYSE: ABT), DuPont Merck, and Bristol-Myers Squibb (NYSE: BMY).
Kozmina holds a Master of Business Administration (MBA) degree from The University of Chicago’s Booth School of Business and earned a postgraduate degree in Chemistry from The Ohio State University. She completed her undergraduate studies in Chemistry at M.V. Lomonosov Moscow State University in Moscow, Russia.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.
Story Continues
Safe Harbor Statement
This news release contains "forward-looking statements" concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the executive leadership of the Company. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106082020/en/
Contacts
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com
View Comments |
| 20.11.24 13:05:21 |
Three Stocks That May Be Trading Below Estimated Value In November 2024 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
As global markets navigate the complexities of policy shifts under the Trump 2.0 administration, investors are witnessing significant movements across various sectors, with financials and energy gaining from deregulation hopes while healthcare and electric vehicle stocks face pressure. Amidst these changes, identifying stocks that may be trading below their estimated value becomes crucial for investors seeking opportunities in a market characterized by volatility and sector-specific fluctuations.
Top 10 Undervalued Stocks Based On Cash Flows
Name Current Price Fair Value (Est) Discount (Est) Taiwan Union Technology (TPEX:6274) NT$156.50 NT$311.70 49.8% Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) CN¥38.67 CN¥76.93 49.7% Giant Biogene Holding (SEHK:2367) HK$48.90 HK$97.74 50% Wistron (TWSE:3231) NT$114.00 NT$227.50 49.9% SISB (SET:SISB) THB31.75 THB63.42 49.9% ConvaTec Group (LSE:CTEC) £2.43 £4.85 49.9% Shoei (TSE:7839) ¥2360.00 ¥4718.51 50% EnomotoLtd (TSE:6928) ¥1475.00 ¥2946.42 49.9% TF Bank (OM:TFBANK) SEK312.00 SEK621.04 49.8% Credit Clear (ASX:CCR) A$0.355 A$0.71 50%
Click here to see the full list of 935 stocks from our Undervalued Stocks Based On Cash Flows screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Applus Services
Overview: Applus Services, S.A. operates in the testing, inspection, and certification industry through its subsidiaries and has a market capitalization of approximately €1.64 billion.
Operations: The company's revenue is primarily derived from its Energy & Industry segment (€1.12 billion), followed by Automotive (€394.94 million), IDIADA (€353.83 million), and Laboratories (€278.31 million).
Estimated Discount To Fair Value: 14.4%
Applus Services is trading at €12.7, approximately 14.4% below its estimated fair value of €14.83, suggesting it may be undervalued based on cash flows. Although the company has a high level of debt and slower revenue growth than the Spanish market, earnings are projected to grow significantly at over 50% annually. Furthermore, Applus is expected to achieve profitability within three years with a strong forecasted return on equity of 24.3%.
Insights from our recent growth report point to a promising forecast for Applus Services' business outlook. Take a closer look at Applus Services' balance sheet health here in our report.BME:APPS Discounted Cash Flow as at Nov 2024
Pluk Phak Praw Rak Mae
Overview: Pluk Phak Praw Rak Mae Public Company Limited specializes in cultivating organic vegetables and fruits in Thailand, with a market cap of THB93.79 billion.
Operations: The company generates revenue primarily from its restaurant business, amounting to THB2.25 billion.
Story Continues
Estimated Discount To Fair Value: 46.2%
Pluk Phak Praw Rak Mae, following its recent IPO raising THB 1.07 billion, is trading at THB 16.6, significantly below its estimated fair value of THB 30.86, highlighting potential undervaluation based on cash flows. The company anticipates robust revenue growth of 22.6% annually and earnings growth of 23.5%, outpacing the Thai market's average growth rates, despite a lower forecasted return on equity of 15.7% in three years.
Our comprehensive growth report raises the possibility that Pluk Phak Praw Rak Mae is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Pluk Phak Praw Rak Mae.SET:OKJ Discounted Cash Flow as at Nov 2024
Ficont Industry (Beijing)
Overview: Ficont Industry (Beijing) Co., Ltd. manufactures and supplies wind turbine tower internals and safety systems for wind turbine manufacturers in China and internationally, with a market cap of CN¥6.04 billion.
Operations: The company generates revenue of CN¥1.34 billion from its Construction Machinery & Equipment segment.
Estimated Discount To Fair Value: 49%
Ficont Industry (Beijing) Co., Ltd. is trading at CNY 28.52, well below its estimated fair value of CNY 55.91, suggesting potential undervaluation based on cash flows. The company reported strong earnings growth of 130.5% over the past year, with future revenue expected to grow at 24.8% annually, surpassing the Chinese market average of 13.9%. However, its return on equity is forecasted to be relatively low at 16.5% in three years.
Our earnings growth report unveils the potential for significant increases in Ficont Industry (Beijing)'s future results. Click here to discover the nuances of Ficont Industry (Beijing) with our detailed financial health report.SHSE:605305 Discounted Cash Flow as at Nov 2024
Turning Ideas Into Actions
Delve into our full catalog of 935 Undervalued Stocks Based On Cash Flows here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Interested In Other Possibilities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:APPS SET:OKJ and SHSE:605305.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 20.11.24 11:05:30 |
UK Stocks Estimated To Be Trading Below Fair Value In November 2024 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
As the United Kingdom's FTSE 100 index grapples with downward pressures stemming from weak trade data out of China, investors are closely monitoring the broader market implications for stocks tied to global economic trends. In such a challenging environment, identifying undervalued stocks that may offer potential value becomes crucial for those looking to navigate through uncertainty and capitalize on opportunities within the UK market.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name Current Price Fair Value (Est) Discount (Est) Gaming Realms (AIM:GMR) £0.3765 £0.73 48.3% ConvaTec Group (LSE:CTEC) £2.43 £4.85 49.9% TBC Bank Group (LSE:TBCG) £32.75 £62.68 47.8% On the Beach Group (LSE:OTB) £1.584 £3.01 47.3% Redcentric (AIM:RCN) £1.165 £2.27 48.6% BATM Advanced Communications (LSE:BVC) £0.195 £0.38 48.4% Auction Technology Group (LSE:ATG) £4.48 £8.54 47.5% Foxtons Group (LSE:FOXT) £0.548 £1.03 46.8% St. James's Place (LSE:STJ) £8.255 £16.31 49.4% Genel Energy (LSE:GENL) £0.816 £1.54 46.9%
Click here to see the full list of 51 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
Let's dive into some prime choices out of the screener.
Victorian Plumbing Group
Overview: Victorian Plumbing Group plc is an online retailer specializing in bathroom products and accessories in the United Kingdom, with a market cap of £364.78 million.
Operations: The company's revenue primarily comes from its online retail segment, which generated £282.90 million.
Estimated Discount To Fair Value: 45.9%
Victorian Plumbing Group is trading at £1.12, significantly below its estimated fair value of £2.07, indicating potential undervaluation based on cash flows. Despite high levels of non-cash earnings, the company has shown a 6.1% earnings growth over the past year and forecasts a robust 36.2% annual profit growth over the next three years, outpacing the UK market's expected growth rate of 14.7%.
According our earnings growth report, there's an indication that Victorian Plumbing Group might be ready to expand. Dive into the specifics of Victorian Plumbing Group here with our thorough financial health report.AIM:VIC Discounted Cash Flow as at Nov 2024
Moonpig Group
Overview: Moonpig Group PLC, with a market cap of £851.17 million, operates in the Netherlands and the United Kingdom offering online greeting cards and gifts through its subsidiaries.
Operations: The company's revenue segments include £51.24 million from Greetz, £241.33 million from Moonpig, and £48.58 million from Experiences.
Estimated Discount To Fair Value: 42.2%
Moonpig Group is trading at £2.47, well below its estimated fair value of £4.27, highlighting potential undervaluation based on cash flows. The company forecasts a 19.21% annual earnings growth, surpassing the UK market's 14.7%. Despite high debt and recent insider selling, Moonpig's revenue growth of 7.6% annually outpaces the broader market rate of 3.5%. Recent share buybacks could further enhance shareholder value by reducing outstanding shares.
Story Continues
Insights from our recent growth report point to a promising forecast for Moonpig Group's business outlook. Click to explore a detailed breakdown of our findings in Moonpig Group's balance sheet health report.LSE:MOON Discounted Cash Flow as at Nov 2024
St. James's Place
Overview: St. James's Place plc is a publicly owned investment manager with a market cap of £4.46 billion, focusing on providing wealth management services.
Operations: The company's revenue segment is primarily derived from its Wealth Management Business, amounting to £26.80 billion.
Estimated Discount To Fair Value: 49.4%
St. James's Place is trading at £8.26, significantly under its fair value estimate of £16.31, suggesting it may be undervalued based on cash flows. Although revenue is projected to decline sharply over the next three years, earnings are expected to grow 27.34% annually and reach profitability within the same period, outperforming market averages. Recent share buyback activities amounting to £32.9 million could enhance shareholder value by reducing outstanding shares and increasing earnings per share potential.
Our earnings growth report unveils the potential for significant increases in St. James's Place's future results. Get an in-depth perspective on St. James's Place's balance sheet by reading our health report here.LSE:STJ Discounted Cash Flow as at Nov 2024
Seize The Opportunity
Investigate our full lineup of 51 Undervalued UK Stocks Based On Cash Flows right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Seeking Other Investments?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:VIC LSE:MOON and LSE:STJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
